Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 24, 2017
| Title: | Process of optically resoluting optically active platinum complex compound |
| Abstract: | Disclosed herein is a process of optically resoluting optically active platinum complex compounds which comprises optically resoluting a d-isomer and an 1-isomer of a cis-Pt(II) complex of a 1,2-cyclohexanediamine isomer characterized in that the mixture of the d-isomer and the 1-isomer is optically resoluted by means of high performance liquid chromatography employing a column packed with a chiral filler. The chiral filler include, for example, a cellulose ester derivative, a cellulose carbamate derivative, an amylose carbamate derivative, a polymethacryl acid ester and .beta.- and .gamma.-cyclodextrin. According to the present invention, the optical resolution of a platinum complex compound essentially consisting of the mixture of two optical isomers which cannot be resoluted in accordance with a normal resolution method due to the small structural difference can be easily performed utilizing the characteristics of a chiral filler. |
| Inventor(s): | Tozawa; Takeshi (Kanagawa, JP), Komoda; Yasunobu (Kanagawa, JP), Ohnishi; Junji (Kanagawa, JP), Masuda; Yukie (Kanagawa, JP), Taniuchi; Junichi (Kanagawa, JP), Nakanishi; Chihiro (Kanagawa, JP), Okamoto; Koji (Kanagawa, JP) |
| Assignee: | Tanaka Kikinzoku Kogyo K.K. (JP) |
| Filing Date: | Apr 07, 1993 |
| Application Number: | 08/043,577 |
| Claims: | 1. A process of optically resoluting an optically active platinum complex compound which comprises optically resoluting a d-isomer and an 1-isomer of a cis-Pt(II) complex of a 1,2-cyclohexane-diamine isomer of Formula (3) [in this Formula, R designates one of Formulae (4), (5), (6), (7), (8) and (9)] characterized in that the mixture of the d-isomer and the 1-isomer is optically resoluted by means of high performance liquid chromatography employing a column packed with a chiral filler ##STR4## 2. A process as claimed in claim 1, wherein the chiral filler is one or more fillers selected the group consisting of a cellulose ester derivative, a cellulose carbamate derivative, an amylose carbamate derivative, a polymethacryl acid ester, .beta.- and .gamma.-cyclodextrin, a polymethacrylamide derivative, an acidic glycoprotein, L-proline, hydroxyproline, L-valine, a filler prepared by adsorbing or binding (1R,2S)-2-carboxymethylamino-1,2-diphenylethanol to silica gel, a filler prepared by coordinating a metal ion to one of the said fillers, a filler prepared by adsorbing or binding a protein to aminated silica gel, a filler packed with a crown ether, a urea derivative chiral to silica gel treated with (3-aminopropyl)triethoxysilane, N(3,5-dinitrobenzoyl)-(R)-phenylglycine, DNB-L-leucine, (S)-1-(.alpha.-naphtyl)ethylamine and a filler chemically bonding to (S)-2-(4-chlorophenyl)isovaloric acid. |
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,398 others who get our Drug Patent Expiration Alerts:
